38 results
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
27 Mar 24
Regulation FD Disclosure
4:26pm
angiogenesis, oxidative stress, and inflammation Oral APX3330 targets earlier-stage DR via multiple pathways Fewer APX3330-treated subjects experienced DR … ." "Ref-1 biology targets three pillars of diabetic eye disease: angiogenesis, inflammation, and oxidative stress. This is promising in the quest
8-K
EX-99.1
pgj4qzdhhn75yvnynoqy
14 Oct 22
Regulation FD Disclosure
11:32am
8-K
EX-99.1
zvketg 9t71tqv1dn
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
8-K
EX-99.2
m3pa3
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
424B3
04be53u5vfcde
2 Oct 20
Prospectus supplement
9:25am
S-4/A
ki6 rnsi1
27 Aug 20
Registration of securities issued in business combination transactions (amended)
5:04pm
S-4
ni5nac93lq7k4 86zex
6 Jul 20
Registration of securities issued in business combination transactions
4:08pm
S-4
EX-10.26
7zqubpmn1gg5rc
6 Jul 20
Registration of securities issued in business combination transactions
4:08pm